|Bid||118.00 x 200|
|Ask||124.10 x 100|
|Day's Range||121.63 - 125.36|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-216.23|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Incyte Corp. a score of 53. Our analysis is based on comparing Incyte Corp. with the following peers – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO Pharmaceuticals, Inc. ... Read more (Read more...)
Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.